Plain-English answer
Hepatitis in China is mainly a hepatitis B and C system challenge. It involves infant vaccination, prevention of mother-to-child transmission, chronic infection diagnosis, antiviral treatment, cirrhosis prevention, liver cancer prevention, stigma, and access to long-term care.
WHO China facts
WHO reports 87 million chronic hepatitis B carriers and 7.6 million people living with chronic hepatitis C in China; hepatitis B and C lead to more than 380,000 cancer-related deaths in China each year.
Why hepatitis is not one disease
Hepatitis A, B, C, D, and E are different viruses with different transmission routes and policy levers. In China, the long-run health burden is especially tied to chronic hepatitis B and C, because chronic infection can progress to cirrhosis and liver cancer. WHO reports that hepatitis B and C are among the most common causes of liver disease and lead to more than 380,000 cancer-related deaths in China each year.
China's hepatitis B vaccination program is a major public-health success. Research on three decades of vaccination policy found that chronic HBV infection among children under 15 fell by about 90 percent compared with the prevaccine era, and by 97 percent among children under 5. That achievement shows the power of birth-dose and infant vaccination. But adult chronic infection remains a huge burden, which is why screening and treatment access are still central.
Why treatment access matters
WHO reports that about 10 percent of people who need hepatitis B treatment in China are currently receiving it. That gap is the difference between vaccine success for future cohorts and continuing cirrhosis and liver cancer risk among adults already infected. For hepatitis C, curative direct-acting antivirals can transform outcomes, but diagnosis, affordability, and linkage to treatment determine whether the benefit reaches patients.
Hepatitis also carries stigma and employment implications. People may avoid testing or disclosure if they fear discrimination. A serious hepatitis page should therefore connect virology to public health, clinical hepatology, oncology prevention, maternal-child health, laboratory testing, and social protection.
Category caution
Do not treat hepatitis as one uniform disease. HBV vaccination, HBV chronic care, HCV cure, liver cancer surveillance, and stigma require different tools.
How to read the pathway
Prevent new HBV infection
Birth-dose vaccination and prevention of mother-to-child transmission are decisive.
Find chronic infection
Screening and linkage to care determine whether adults with HBV or HCV are treated.
Prevent liver cancer
Antiviral therapy, cirrhosis care, and surveillance connect hepatitis to oncology outcomes.
Strategic meaning
For strategy, hepatitis connects vaccines, maternal-child health, diagnostics, antivirals, hepatology, oncology, and insurance. The highest-value interventions are those that close cascade gaps: timely birth dose, maternal screening, HBV DNA testing, antiviral access, HCV cure, and surveillance for cirrhosis and hepatocellular carcinoma. The buyer and evidence standard differ depending on whether the intervention is prevention, diagnosis, treatment, or cancer surveillance.
Research anchors
| Source | What it adds | How to use it |
|---|---|---|
| WHO hepatitis in China | Provides chronic HBV/HCV counts, cancer-death linkage, and treatment gap. | Use it for current burden. |
| Prevention of chronic hepatitis B after vaccination policy | Quantifies the reduction in chronic HBV among children after vaccination expansion. | Use it for prevention success. |
| 2024 HBV epidemiology report | Summarizes vaccination coverage, MTCT prevention, and remaining HBV challenges. | Use it for updated HBV trajectory. |